Cadence Pharmaceuticals, Inc. (CADX) Reports In-Line Q3 EPS

Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) reported Q3 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $13.9 million versus the consensus estimate of $14.16 million.

As of November 5, 2012, Cadence expects that net product revenue from sales of OFIRMEV for the three months ending December 31, 2012, will range from approximately $15.9 million to $16.4 million.

For earnings history and earnings-related data on Cadence Pharmaceuticals, Inc. (CADX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Top AI Semiconductor Stocks According to Stifel Analysis
• Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
• CLSA Starts Gravita India Ltd (GRAV:IN) at Outperform (2)